Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).
The pharmaceutical industry is evolving due to new regulations and technological developments. Distributors like Biesterfeld play a central role in supporting manufacturers in their daily operations.
Hans Van Hees will join Bachem's Corporate Executive Committee as global Chief Operations Officer (COO) on September 1, 2025.
AbbVie announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the US.
Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden.
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
Sygnature Discovery, an integrated drug discovery CRO, has completed a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment.
AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.
Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced that Geoffrey M. Glass has been appointed Chief Executive Officer, effective immediately.
Sanner, a provider of high-quality healthcare packaging and drug delivery solutions, officially opened its first US-based production facility in Greensboro, North Carolina.
The Validation 4.0 Guide provides a comprehensive approach to ensuring product quality and patient safety throughout a pharmaceutical product's lifecycle.
Roquette Appoints Thierry Fournier as Chief Executive Officer
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Pace Life Sciences, a US-based contract research, development, and manufacturing organization (CRDMO), is remodeling and expanding its Salem, NH site for aseptic fill-finish processing.
AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs).
Axplora to expand its Farmabios site in Gropello Cairoli, Italy, with a €35 million investment.
Vetter broke ground for the start of construction of its new clinical site in Des Plaines, Illinois, US on June 26.
IMCD, a global partner for the distribution and formulation of speciality chemicals and ingredients, has acquired Trichem, an Indian pharmaceutical supplier.
Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK.
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025.
Schott Pharma is investing more than €100 million in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.
Resilience recently shared that capacity expansions have exceeded current industry demand. As a result, Resilience has begun consolidating its operations and streamlining its business strategy.
Brenntag recently announced the acquisition of MCE Pharma to strengthen Brenntag’s capabilities across the entire pharmaceutical and biopharmaceutical value chain.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology.
Sterling Pharma Solutions to produce an antibody-drug conjugate (ADC) candidate for Kivu Bioscience.
Sanofi to acquire Vigil Neuroscience, a clinical-stage biotech focused on therapies for neurodegenerative diseases.
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
PCI Pharma Services has completed its acquisition of Ajinomoto Althea, a CDMO subsidiary of Ajinomoto.
Roquette completes IFF Pharma Solutions acquisition and unveils new structure for global growth and innovation.
MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.
An Attractive and Highly Sought-after Business Location
The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.
South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.
Consulting firm BCG has evaluated the effectiveness of biotech innovation centers in Europe and the USA. Adolphs explains what is lacking in Germany in particular.
